News headlines about Infinity Pharmaceuticals (NASDAQ:INFI) have trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Infinity Pharmaceuticals earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 90 out of 100, indicating that recent press coverage is very likely to have an effect on the stock’s share price in the immediate future.
These are some of the media stories that may have effected Accern’s scoring:
- WellCare Health Plans, Inc. (WCG) noted a price change of -0.05% and Infinity Pharmaceuticals, Inc. (INFI) closes … – Stocks Gallery (stocksgallery.com)
- Analysts Suggest to Hold stock: Infinity Pharmaceuticals, Inc. (INFI) – Street Observer (press release) (streetobserver.com)
- Infinity (INFI) Q2 Loss Wider than Expected, View Intact – Nasdaq (nasdaq.com)
- Ichimoku Levels Point to Negative Momentum For Infinity Pharmaceuticals Inc (INFI) – Evergreen Caller (evergreencaller.com)
- Infinity Pharmaceuticals’ (INFI) CEO Adelene Perkins on Q2 2017 Results – Earnings Call Transcript – Seeking Alpha (seekingalpha.com)
Infinity Pharmaceuticals (NASDAQ:INFI) traded down 4.44% during midday trading on Tuesday, reaching $1.29. 472,924 shares of the company traded hands. Infinity Pharmaceuticals has a 12 month low of $0.84 and a 12 month high of $3.84. The firm has a market capitalization of $65.07 million, a PE ratio of 645.00 and a beta of 2.60. The company’s 50-day moving average price is $1.54 and its 200 day moving average price is $2.11.
Infinity Pharmaceuticals (NASDAQ:INFI) last released its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.22) by $0.12. During the same quarter in the prior year, the firm posted $1.05 EPS. On average, equities analysts anticipate that Infinity Pharmaceuticals will post ($0.89) earnings per share for the current year.
A number of brokerages have recently commented on INFI. ValuEngine upgraded shares of Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, July 6th. Zacks Investment Research cut shares of Infinity Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, May 16th. Six investment analysts have rated the stock with a hold rating, The stock has a consensus rating of “Hold” and a consensus target price of $1.17.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive News Coverage Very Likely to Impact Infinity Pharmaceuticals (INFI) Stock Price” was posted by BBNS and is the sole property of of BBNS. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://baseballnewssource.com/markets/infinity-pharmaceuticals-infi-getting-somewhat-favorable-media-coverage-study-shows-updated-updated-updated/1197038.html.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
Receive News & Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.